Pneumologie 2010; 64(3): 149-154
DOI: 10.1055/s-0029-1243910
Guideline

© Georg Thieme Verlag KG Stuttgart · New York

Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community-acquired Pneumonia

Summary of the Update 2009G.  Höffken1 , 2 , J.  Lorenz2 , W.  Kern3 , T.  Welte2 , 4 , T.  Bauer1 , 2 , K.  Dalhoff2 , E.  Dietrich1 , S.  Ewig1 , 2 , P.  Gastmeier1 , B.  Grabein1 , E.  Halle1 , M.  Kolditz2 , R.  Marre3 , 4 , H.  Sitter5
  • 1for the Paul-Ehrlich-Society of Chemotherapy
  • 2for the German Respiratory Diseases Society
  • 3for the German Infectious Diseases Society
  • 4for the competence network CAPNETZ
  • 5for the Arbeitsgemeinschaft Wissenschaftlicher Medizinischer Fachgesellschaften AWMF
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
23. Februar 2010 (online)

Preview

Summary Update 2009

This summary of the update of the guidelines for the management of lower respiratory tract infections and community-acquired pneumonia (CAP) provides an overview on the structure and key points provided in this document. It is based on the structure of the Oxford Centre of Evidence Based Medicine.

The update refers to important new insights from studies published by the CAPNETZ and the Bundesgeschäftsstelle für Qualitätssicherung (BQS). Essential new statements as compared to the original 2005 version include the following: 1) treatment of patients with acute exazerbation of COPD (restrictive indications for antimicrobial treatment); 2) preference for the CRB-65 score as tool for the validation of clinical assessment of pneumonia severity; 3) treatment of patients with mild CAP (oral cephalosporins no longer recommended); 4) treatment of patients with moderate CAP (ertapenem as new option in selected cases); 5) treatment of patients with severe CAP (antipseudomonal treatment only rarely indicated; reintroduction of aminoglycosides as agent in combination treatment); 6) reduction of treatment duration; 7) new focus on palliative treatment of patients with CAP.

Selected References

Prof. Dr. med. G. Höffken

Universitätsklinikum Carl Gustav Carus Dresden
Medizinische Klinik I

Fetscherstr. 74
01307 Dresden

eMail: gert.hoeffken@uniklinikum-dresden.de


Fachkrankenhaus Coswig

Neucoswiger Str. 21
01640 Coswig

eMail: prof.hoeffken@fachkrankenhaus-coswig.de